A differentiated approach to healthcare venture
Since 2008, the NEMO (New Emerging Medical Opportunities) family of late-stage venture capital funds has invested in innovative biotech and medtech companies across North America and Europe. In 2023, we launched the Fonds Medtech Ventures (FMV), which focuses on Canadian medtech companies. We use funds and the operational expertise of our entire team to help our companies bring novel therapeutics and medical devices to patients around the world. Our investment philosophy is grounded in the belief that financial performance can go hand in hand with driving lasting benefits for society through improved health and well-being.